The longevity protocol: growth-hormone-axis peptides, and what they can and cannot do

There's no official longevity protocol. The term describes a common pattern: a course of a GHRH analog plus a GHRP, dosed to raise growth hormone and its downstream messenger IGF-1 back toward the levels of a younger adult, usually alongside resistance training, sleep, and nutrition work.

The reasoning runs like this: as the GH pulse fades with age, so goes some of what we notice about getting older — fat around the middle, less muscle, slower recovery, shallower sleep. Coax that pulse back gently, with the body's own brakes still working, and you sidestep the bluntness of injecting growth hormone outright. It's a reasonable premise. What it isn't is a settled one — whether it actually buys otherwise-healthy adults meaningful benefit over years is the question the evidence still hasn't answered.

The pairing works because the two peptides hit growth-hormone release through two different receptors.

Sermorelin is a 29-amino-acid fragment of growth-hormone-releasing hormone. It binds the GHRH receptor on the pituitary and prompts it to release GH in natural pulses, with the body's feedback brake (somatostatin) still in place ^[1]. CJC-1295 is a longer-acting GHRH analog; in its DAC form it binds albumin and sustains GHRH tone over days rather than producing a short pulse ^[5][6]. Either one plays the "GHRH" role.

Ipamorelin is a selective GHRP — a ghrelin-receptor (GHSR-1a) agonist — that triggers a GH pulse without meaningfully raising cortisol, ACTH or prolactin, which is what set it apart from older GHRPs ^[3]. It supplies the pulse.

Run together, a GHRH analog and a GHRP produce more GH than either alone — a genuinely synergistic effect on secretion documented in mechanistic human work by Veldhuis and Bowers and well established at the level of pituitary physiology ^[9]. Clinicians describe the combination as "pulse and sustain": the GHRP drives the acute release, the GHRH analog raises the baseline it releases against.

Here's the honest boundary. The secretion effect is real and measured: these peptides raise GH and IGF-1. The two adult studies people cite most are worth looking at directly. Corpas and colleagues gave a GHRH peptide to nine young and ten elderly men over 14 days; the high-dose arm lifted mean 24-hour GH, peak GH amplitude, and IGF-1 in the elderly group toward the range seen in the young controls ^[10]. Khorram and colleagues ran a 16-week single-blind, placebo-controlled trial of nightly GHRH-analog dosing in older adults and reported real increases in GH release and higher 12-hour mean GH at both 4 and 16 weeks.

But notice what those are: small samples, short durations, biomarker endpoints. There is no Phase 3 trial of sermorelin in adults, and no long-term outcome data on body composition, fracture risk, cardiovascular events, or mortality. Expert reviews — Walker in 2006, Sigalos and Pastuszak in 2018 — synthesize the evidence into a generally favorable but cautious assessment, not a ringing endorsement ^[11][12]. And for the specific GHRH-analog-plus-GHRP combination, there's no published human randomized trial testing it for any clinical longevity endpoint at all.

So the leap from "more GH pulse" to "healthier aging" is an extrapolation. People who feel better on these protocols are reporting a real experience, but self-reports and biomarker shifts aren't the same as demonstrated long-term benefit — and the people who report the most tend to be those who started from a genuine deficit, not healthy adults with normal baseline IGF-1.

The GHRP side of the stack is almost always ipamorelin. The GHRH side is where the real choice sits, and the three main options behave differently.

Sermorelin produces a short, natural pulse — it clears from plasma in minutes — which is why it's dosed at night to ride the body's own GH rhythm. Its appeal is that it's the most physiologic and, as covered below, the cleanest regulatory case.

CJC-1295, especially the DAC version, does the opposite: it sustains GHRH signaling for days, producing steadier IGF-1 rather than discrete pulses ^[6]. Some clinicians see that as convenient; others argue that flattening the pulse gives up part of what made the peptide approach attractive in the first place.

Tesamorelin is the reference point worth knowing, because it's the one GHRH-class drug that's actually FDA-approved. It was approved in 2010 (as Egrifta) ^[7] and remains the only approved GHRH-class product on the US market ^[8] — but its approved indication is reducing excess visceral fat in HIV-associated lipodystrophy, not anti-aging or longevity. That distinction matters: it proves the GHRH mechanism can clear the bar for a specific, studied indication, while underlining that "the mechanism is approvable" is not the same as "this longevity use is approved." Tesamorelin is a prescription brand drug with brand pricing, used off-label for body composition by some clinics, and it carries the same IGF-1 caution as the rest of the class.

Because none of this is FDA-approved for anti-aging use, there's no established clinical dose — only clinic- and user-reported patterns, offered here as context, not instruction.

The reported shape is a low nightly dose timed to the body's natural GH pulse: a GHRH analog and ipamorelin, each in the low-hundreds-of-micrograms range, injected subcutaneously before bed, often cycled — a common pattern is five days on, two off — to limit receptor desensitization. The reason timing is built around sleep rather than convenience is pharmacokinetic: sermorelin clears in minutes and ipamorelin peaks around 40 minutes ^[1][4], so a bedtime dose lands the extra pulse during the window when the body would naturally produce one. Both come as a freeze-dried powder reconstituted with bacteriostatic water. Courses are typically run in blocks with breaks rather than continuously, and — the part that isn't optional — built around bloodwork.

There's no trial-validated timeline, so what follows is the arc clinicians and users commonly describe, not a promise. Sleep tends to be the first thing people report shifting, often within the first few weeks — deeper, more consolidated. Recovery and steadier daytime energy are the next to come up, over roughly the following one to three months. Body-composition changes — modest reductions in visceral fat, small gains in lean mass — are reported later still, in the three-to-six-month range, and mostly in people also doing resistance training; the Khorram body-composition data over 16 weeks is broadly consistent with that, though the sample is far too small to fix the magnitude.

What the protocol reliably does not do, whatever a clinic's website implies: it doesn't reverse aging, it doesn't match the body-composition effects of growth hormone or testosterone replacement, and it does little for someone whose baseline IGF-1 is already normal. Judge it on that realistic scale, with a defined review point, rather than on transformation-story expectations.

Monitoring is the part you don't skip. Done responsibly, this means IGF-1 bloodwork — usually every 6 to 12 weeks — both to check that it's working and, more to the point, to stop IGF-1 climbing higher than it should. That one lab is the guardrail. It's also why this sits with a prescriber and not with a syringe and a forum thread.

There's a diagnostic point underneath that, too. The adults with the clearest rationale are those with documented, age-adjusted low IGF-1 and symptoms that fit — poor sleep architecture, central fat that won't shift, slow recovery — which is something an endocrine workup establishes, not a quiz on a telehealth site. Anyone with diabetes or insulin resistance needs glucose watched alongside IGF-1, since growth hormone works against insulin. Baseline labs before starting, and periodic labs during, are what separate a supervised protocol from an experiment on yourself.

The appeal of this approach — working with the body's own feedback loops — is also its main safety argument: unlike injected growth hormone, a sermorelin or ipamorelin pulse still answers to somatostatin, so the system can brake itself. That's a real advantage. It is not a guarantee of safety.

IGF-1 is where the real worry lives. It's a growth signal, and the epidemiology ties chronically high IGF-1 to a raised risk of certain cancers. That's the whole reason the lab above isn't optional — and the reason anyone with a current or recent malignancy shouldn't touch GH-axis peptides without an oncologist in the room. GH also pulls against insulin, so if you're diabetic or insulin-resistant, glucose needs watching closely. These peptides are inappropriate in pregnancy and breastfeeding; untreated hypothyroidism blunts the GH response and should be corrected first; and growth-hormone secretagogues are on the WADA Prohibited List, so competitive athletes risk a positive test ^[16].

This is where the pieces of the "longevity protocol" diverge, and it matters for what you can actually and legally obtain in mid-2026.

Sermorelin is the cleanest case. It was FDA-approved in 1997 (as Geref) for pediatric growth-hormone deficiency and discontinued in 2009 for business, not safety, reasons — a determination the FDA formally confirmed in 2013 ^[2]. Because it was pulled commercially rather than for safety, licensed 503A pharmacies can compound it with a prescription, and it was never placed on the FDA's Category 2 list ^[15].

Ipamorelin and CJC-1295 are less settled. Both were placed in Category 2 in 2023, then removed in 2024 (alongside AOD-9604, thymosin alpha-1 and Selank) and referred to the Pharmacy Compounding Advisory Committee ^[13]. As of mid-2026 neither has been added to the approved 503A Bulks List, and neither was on the FDA's July 23–24, 2026 PCAC agenda ^[14] — so there's no clearly established compounding pathway for them yet, and availability varies. In practice a pharmacy may be able to prepare the sermorelin half of a protocol but not the ipamorelin or CJC-1295 half. Tesamorelin, by contrast, is an approved brand product — available by prescription, at brand cost, for its approved indication. Confirm current, state-specific status with a licensed clinician before planning around any of it.

Longevity conversations often fold in other peptides — epitalon, NAD+, and MOTS-c among them — aimed at circadian, cellular-energy, and mitochondrial pathways rather than growth hormone. They belong to a different mechanistic story, and the human evidence for each is generally earlier-stage than even the GH-axis data. We cover them individually rather than bundling them here, because stacking several under-studied peptides at once multiplies the unknowns, not the benefits. Follow the links for the peptide-by-peptide detail.